Surgery may not Be Necessary for Late-stage Colorectal Cancers

Article

A new study from Memorial Sloan-Kettering Cancer Center indicates that the majority of patients who present with stage IV colorectal cancer do not require immediate surgery to remove their primary tumor.

Patients with stage IV colon cancer often undergo colon surgery immediately following their diagnosis to prevent symptoms and complications from their tumor, such as bowel obstruction, bleeding, and perforation, and then start chemotherapy 3 to 6 weeks later. Now, a new study from Memorial Sloan-Kettering Cancer Center (MSKCC) indicates that the majority of patients who present with stage IV colorectal cancer do not require immediate surgery to remove their primary tumor.

The study was a retrospective review that examined 233 metastatic colorectal cancer cases treated at MSKCC from 2000 to 2006. Patients were included if they were initially diagnosed with stage IV disease; there was no major bleeding, perforation, or obstruction of the colon; and the initial treatment was combination chemotherapy at MSKCC. Of the patients evaluated, 207 (89%) never developed colon problems that required urgent surgery, 10 (4%) developed colon obstruction that was successfully treated using a nonsurgical approach (stent placement or radiation), 16 (7%) required nonelective colon surgery for obstruction (n = 13) or perforation (n = 3); and 2 (0.8%) died secondary to surgical intervention; thus, the vast majority of patients (93%) of patients never required surgery to manage their primary tumor.

As a result of these findings, the investigators suggest the standard of practice for this patient population should be a nonsurgical approach, as it eliminates the costs and risks of colon surgery and allows the patient's metastatic disease--instead of just their primary tumor--to be treated without delay. Philip B. Patty, MD, a surgical oncologist at MSKCC and one of the study's lead authors, concluded “We now know that the routine use of surgery for these patients is based on old thinking, and we're beyond that. There will always be the need for individual exceptions based on the clinical situation, but our default position should be not to operate.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.